This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krakoff, J. Articles by Nieman, L. K. Search for Related Content PubMed PubMed Citation Articles by Krakoff, J. Articles by Nieman, L. K.

Use of a Parenteral Propylene Glycol-Containing Etomidate Preparation for the Long-Term Management of Ectopic Cushing’s Syndrome

National Institute of Diabetes and Digestive and Kidney Diseases (J.K.), National Institutes of Health, Phoenix, Arizona 85014; and Pediatric and Reproductive Endocrinology Branch (C.A.K.), National Institute of Child Health and Human Development (C.A.K., L.K.N.); Clinical Center Pharmacy (K.A.C.); and Surgery Branch, National Cancer Institute (R.H.A.), National Institutes of Health, Bethesda, Maryland 20892

Address all correspondence and requests for reprints to: Jonathan Krakoff, M.D., National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 1550 East Indian School Road, Phoenix, Arizona 85014. E-mail: jkrakoff{at}mail.nih.gov

Abstract

Chronic severe hypercortisolism is associated with life-threatening infections, diabetes and a high surgical mortality rate. Oral medical therapy can inhibit steroidogenesis and reduce the risk of these complications. However, apart from a few reports using an ethyl alcohol formulation of the iv anesthetic etomidate, there is no well-tested parenteral steroidogenesis inhibitor. We used the propylene glycol preparation of etomidate available in the United States to control hypercortisolism in a 39-yr-old man with ectopic ACTH secretion who was unable to take oral medications. Etomidate was administered over a period of 5.5 months. We titrated the dose of etomidate daily using serum cortisol levels, to avoid steroid over replacement and allow for a response to ongoing stress. A reduced dose during a period of acute renal failure achieved adequate control of hypercortisolemia. Suppression of steroidogenesis persisted for at least 14 d and perhaps as long as 6 wk after cessation of the medication. Except for transient myoclonus, the patient tolerated this preparation well. Parenteral propylene glycol containing etomidate can be used safely for a prolonged period to reduce hypercortisolemia in patients unable to take oral medications.

This article has been cited by other articles:

				I. Veytsman, L. Nieman, and T. Fojo Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma J. Clin. Oncol., September 20, 2009; 27(27): 4619 - 4629. [Abstract] [Full Text] [PDF]

				A. Dabbagh, N. Sa'adat, and Z. Heidari Etomidate Infusion in the Critical Care Setting for Suppressing the Acute Phase of Cushing's Syndrome Anesth. Analg., January 1, 2009; 108(1): 238 - 239. [Abstract] [Full Text] [PDF]

				B. M. K. Biller, A. B. Grossman, P. M. Stewart, S. Melmed, X. Bertagna, J. Bertherat, M. Buchfelder, A. Colao, A. R. Hermus, L. J. Hofland, et al. Treatment of Adrenocorticotropin-Dependent Cushing's Syndrome: A Consensus Statement J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2454 - 2462. [Abstract] [Full Text] [PDF]

				M. Christ-Crain, S. Jutla, I. Widmer, O. Couppis, C. Konig, H. Pargger, J. Puder, R. Edwards, B. Muller, and A. B. Grossman Measurement of Serum Free Cortisol Shows Discordant Responsivity to Stress and Dynamic Evaluation J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1729 - 1735. [Abstract] [Full Text] [PDF]

				J. B. Lundy, M. L. Slane, and J. D. Frizzi Acute Adrenal Insufficiency After a Single Dose of Etomidate J Intensive Care Med, March 1, 2007; 22(2): 111 - 117. [Abstract] [PDF]

				T. N Johnson and T. W Canada Etomidate Use for Cushing's Syndrome Caused by an Ectopic Adrenocorticotropic Hormone-Producing Tumor Ann. Pharmacother., February 1, 2007; 41(2): 350 - 353. [Abstract] [Full Text] [PDF]

				F. Esposito, J. R. Dusick, P. Cohan, P. Moftakhar, D. McArthur, C. Wang, R. S. Swerdloff, and D. F. Kelly Early Morning Cortisol Levels as a Predictor of Remission After Transsphenoidal Surgery for Cushing's Disease J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 7 - 13. [Abstract] [Full Text] [PDF]

				I. Ilias, D. J. Torpy, K. Pacak, N. Mullen, R. A. Wesley, and L. K. Nieman Cushing's Syndrome Due to Ectopic Corticotropin Secretion: Twenty Years' Experience at the National Institutes of Health J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4955 - 4962. [Abstract] [Full Text] [PDF]

				K. Miehle, A. Tannapfel, P. Lamesch, G. Borte, E. Schenker, R. Kluge, R. A. Ott, V. Wiechmann, M. Koch, W. Kassahun, et al. Pancreatic Neuroendocrine Tumor with Ectopic Adrenocorticotropin Production upon Second Recurrence J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3731 - 3736. [Abstract] [Full Text] [PDF]